Dianthus Therapeutics (DNTH) Assets (2017 - 2025)

Dianthus Therapeutics has reported Assets for 9 years, with the latest figure at $530.9 million in Q4 2025.

• For the quarter ending Q4 2025, Assets rose 41.95% year-over-year to $530.9 million; the trailing twelve-month figure through Dec 2025 stood at $530.9 million (up 41.95% YoY), and the FY2025 full-year result was $530.9 million, up 41.95% from the prior year.
• Assets for Q4 2025 stood at $530.9 million, down from $577.4 million in the prior quarter.
• The five-year high for Assets was $577.4 million in Q3 2025, with the low at $78.6 million in Q2 2023.
• Average Assets over 5 years is $258.7 million, with a median of $200.3 million recorded in 2021.
• Year-over-year, Assets sank 57.07% in 2023 and surged 369.19% in 2024.
• Tracing DNTH's Assets over 5 years: stood at $189.9 million in 2021, then slumped by 56.24% to $83.1 million in 2022, then soared by 115.86% to $179.4 million in 2023, then surged by 108.47% to $374.0 million in 2024, then soared by 41.95% to $530.9 million in 2025.
• The last three Assets figures came in at $530.9 million (Q4 2025), $577.4 million (Q3 2025), and $326.1 million (Q2 2025), per Business Quant data.

Peer Comparison